260 related articles for article (PubMed ID: 33389440)
21. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.
Jaiswal G; Yaduvanshi S; Kumar V
J Biomol Struct Dyn; 2022 Sep; 40(14):6671-6681. PubMed ID: 33645443
[TBL] [Abstract][Full Text] [Related]
22.
Tiwari V
Biol Open; 2020 Oct; 9(10):. PubMed ID: 32878881
[TBL] [Abstract][Full Text] [Related]
23. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
24. Short Amphiphiles or Micelle Peptides May Help to Fight Against COVID-19.
Manna S; Chowdhury T; Mandal SM; Choudhury SM
Curr Protein Pept Sci; 2022; 23(1):33-43. PubMed ID: 35086446
[TBL] [Abstract][Full Text] [Related]
25. Probing the competitive inhibitor efficacy of frog-skin alpha helical AMPs identified against ACE2 binding to SARS-CoV-2 S1 spike protein as therapeutic scaffold to prevent COVID-19.
Sekar PC; Srinivasan E; Chandrasekhar G; Paul DM; Sanjay G; Surya S; Kumar NSAR; Rajasekaran R
J Mol Model; 2022 Apr; 28(5):128. PubMed ID: 35461388
[TBL] [Abstract][Full Text] [Related]
26. A new DNA aptamer which binds to SARS-CoV-2 spike protein and reduces pro-inflammatory response.
Kim W; Song ES; Lee SH; Yang SH; Cho J; Kim SJ
Sci Rep; 2024 Mar; 14(1):7516. PubMed ID: 38553521
[TBL] [Abstract][Full Text] [Related]
27. Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.
Alves Ferreira-Bravo I; DeStefano JJ
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696413
[TBL] [Abstract][Full Text] [Related]
28. The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms.
Paiardi G; Richter S; Oreste P; Urbinati C; Rusnati M; Wade RC
J Biol Chem; 2022 Feb; 298(2):101507. PubMed ID: 34929169
[TBL] [Abstract][Full Text] [Related]
29. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
[TBL] [Abstract][Full Text] [Related]
30. Phytoconstituents from Moringa oleifera fruits target ACE2 and open spike glycoprotein to combat SARS-CoV-2: An integrative phytochemical and computational approach.
Siddiqui S; Ahmad R; Alaidarous M; Zia Q; Ahmad Mir S; Alshehri B; Srivastava A; Trivedi A
J Food Biochem; 2022 May; 46(5):e14062. PubMed ID: 35043973
[TBL] [Abstract][Full Text] [Related]
31. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
Souza PFN; Amaral JL; Bezerra LP; Lopes FES; Freire VN; Oliveira JTA; Freitas CDT
J Biomol Struct Dyn; 2022 Aug; 40(12):5493-5506. PubMed ID: 33427102
[TBL] [Abstract][Full Text] [Related]
32. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
33. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
Toor HG; Banerjee DI; Lipsa Rath S; Darji SA
Eur J Pharmacol; 2021 Jan; 890():173720. PubMed ID: 33160938
[TBL] [Abstract][Full Text] [Related]
34. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve
Shiliaev N; Lukash T; Palchevska O; Crossman DK; Green TJ; Crowley MR; Frolova EI; Frolov I
J Virol; 2021 Oct; 95(21):e0135721. PubMed ID: 34406867
[TBL] [Abstract][Full Text] [Related]
35. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
36. Molecular dynamic simulation analysis of SARS-CoV-2 spike mutations and evaluation of ACE2 from pets and wild animals for infection risk.
Chen P; Wang J; Xu X; Li Y; Zhu Y; Li X; Li M; Hao P
Comput Biol Chem; 2022 Feb; 96():107613. PubMed ID: 34896769
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Peptides as Promising Therapeutics against SARS-CoV-2.
Chowdhury SM; Talukder SA; Khan AM; Afrin N; Ali MA; Islam R; Parves R; Al Mamun A; Sufian MA; Hossain MN; Hossain MA; Halim MA
J Phys Chem B; 2020 Nov; 124(44):9785-9792. PubMed ID: 33095007
[TBL] [Abstract][Full Text] [Related]
39. A Universal DNA Aptamer that Recognizes Spike Proteins of Diverse SARS-CoV-2 Variants of Concern.
Zhang Z; Li J; Gu J; Amini R; Stacey HD; Ang JC; White D; Filipe CDM; Mossman K; Miller MS; Salena BJ; Yamamura D; Sen P; Soleymani L; Brennan JD; Li Y
Chemistry; 2022 Mar; 28(15):e202200078. PubMed ID: 35084794
[TBL] [Abstract][Full Text] [Related]
40. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
